The Japanese pharma company Eisai is doubling down on its efforts to find new dementia drugs — and opening a new dementia-focused startup incubator.
The company is creating the incubator as part of its plan to move its Massachusetts-based research staff from Andover, Mass., to Cambridge, Mass., on May 20. As in Andover, the staff at the Cambridge facility will focus on finding new drugs targeting inflammation in the brain; some studies have shown a link between inflammation and dementia. Accordingly, the new Cambridge center is referred to as the Eisai Center for Genetics Guided Dementia Discovery or G2D2; the incubator itself will be called the Eisai Incubator for NeuroDiscovery, or e-IND.
The incubator’s launch comes just a few months after Eisai and Biogen halted clinical trials of an Alzheimer’s drug, aducanumab — but this particular move has been planned for at least a year.